

Contents

| | |
|---------------------------------------------------------------------------------------------------------------------------------|-------------|
| Abbreviations | vi |
| Preface | vii |
| Acknowledgements | viii |
| 1. Major primary prevention trials with statins | 1 |
| West Of Scotland Coronary Prevention Study (WOSCOPS) | 2 |
| Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) | 4 |
| Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial—Lipid-Lowering Trial (ALLHAT—LLT) | 6 |
| PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) | 8 |
| Primary prevention of CV disease with pravastatin in Japan (MEGA) | 10 |
| Primary prevention of CV disease with statin therapy: a meta-analysis of randomized controlled trials | 12 |
| Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) | 14 |
| 2. Major secondary prevention trials with statins | 17 |
| Scandinavian Simvastatin Survival Study (4S) | 18 |
| Cholesterol and Recurrent Events (CARE) | 20 |
| Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) | 22 |
| Heart Protection Study (HPS) | 24 |
| 3. Early statin treatment in ACS patients | 27 |
| Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) | 28 |
| Effects of early treatment with statins on short-term clinical outcomes in ACS: a meta-analysis of randomized controlled trials | 30 |
| Atorvastatin for Reduction of MYocardial Damage during Angioplasty (ARMYDA)—ACS | 32 |
| 4. CHD prevention trials with statins in patients with diabetes or the metabolic syndrome | 35 |
| HPS diabetes subgroup analysis | 36 |
| LIPID post-hoc subgroup analysis | 38 |
| Collaborative AtoRvastatin Diabetes Study (CARDS) | 40 |
| Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT—LLA) post-hoc diabetes subgroup analysis | 42 |
| Treating to New Targets (TNT) diabetes subgroup analysis | 44 |
| TNT post-hoc metabolic syndrome subgroup analysis | 46 |

Published by Cedilla Publishing Limited
PO Box 58871, London SE15 9BE, UK
Telephone: +44 (0)7794 485294
www.cedillapublishing.com

© 2008, 2010 Cedilla Publishing Limited

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the copyright owner.

The publisher and authors have made every effort to ensure the accuracy of the information in this book, but cannot accept responsibility for any errors or omissions. Any product mentioned in this publication should be used in accordance with the local prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

British Library Cataloguing in Publication Data

A catalogue for this book is available from the British Library.

ISBN: 978-1-905982-06-6 second edition
(978-1-905982-03-5 first edition)

10 9 8 7 6 5 4 3 2 1

Cover image: Fat cells

Manfred Kage, Peter Arnold Inc. / Science Photo Library

Printed by Halstan Ideal in the UK.

| | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|----------------------------------------------------------------------------------------------------------------------------------|------------|
| Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN) | 48 | | |
| 5. CHD prevention in chronic kidney disease | 51 | | |
| Die Deutsche Diabetes Dialyse (4D) Studie | 52 | | |
| 4S post-hoc mild chronic renal insufficiency subgroup analysis | 54 | | |
| Statins and CV RR in patients with chronic kidney disease and end-stage renal failure | 56 | | |
| 6. Stroke prevention | 59 | | |
| Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) | 60 | | |
| Impact of statins on risk of stroke | 62 | | |
| 7. Comparative hypolipidaemic efficacy, IVUS, IMT and end-point trials | 65 | | |
| Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (CURVES) | 66 | | |
| Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) | 68 | | |
| Statin Therapies for Elevated Lipid Levels compared Across dose ranges to Rosuvastatin (STELLAR) | 70 | | |
| Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I) | 72 | | |
| Reversal of atherosclerosis with aggressive lipid lowering therapy (REVERSAL) | 74 | | |
| PRavastatin Or atorVastatin Evaluation and Infection Therapy—Thrombolysis In Myocardial Infarction 22 (PROVE-IT TIMI 22) | 76 | | |
| VYtorin Versus Atorvastatin (VYVA) | 78 | | |
| Ezetimibe Add-on to Statin for Effectiveness (EASE) | 80 | | |
| TNT | 82 | | |
| Incremental Decrease in End points through Aggressive Lipid lowering (IDEAL) | 84 | | |
| VYTAL study | 86 | | |
| A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) | 88 | | |
| Meta-analysis of CV outcomes trials comparing intensive vs moderate statin therapy | 90 | | |
| Measuring Effects on intima-media Thickness: an Evaluation Of Rosuvastatin (METEOR) | 92 | | |
| Ezetimibe aNd simvastatin in Hypercholesterolemia enhANces atherosClerosis rEgression (ENHANCE) | 94 | | |
| Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) | 96 | | |
| Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol 6-HDL And LDL Treatment Strategies (ARBITER6-HALTS) | 98 | | |
| | | 8. Meta-analyses for efficacy, safety and cost-benefit calculations | 101 |
| | | Cholesterol Treatment Trialists (CTT) | 102 |
| | | Aspirin, statins or both drugs for the primary prevention of CHD events in men: a cost-utility analysis | 104 |
| | | Analyses of cancer data from three ezetimibe trials | 106 |
| | | Primary prevention strategies for lipid lowering: a meta-analysis | 108 |
| | | 9. Primary prevention trials with CHD end points using drugs that modify triglyceride-rich lipoproteins and/or HDL | 111 |
| | | World Health Organization (WHO) clofibrate study | 112 |
| | | Helsinki Heart Study (HHS) | 114 |
| | | Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS) | 116 |
| | | 10. Secondary prevention trials with CHD end points using drugs that modify triglyceride-rich lipoproteins and/or HDL | 119 |
| | | Coronary Drug Project | 120 |
| | | Veterans Affairs HDL Intervention Trial (VA-HIT) | 122 |
| | | Bezafibrate Infarction Prevention (BIP) | 124 |
| | | HDL Atherosclerosis Treatment Study (HATS) | 126 |
| | | Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) | 128 |
| | | Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) | 130 |
| | | Appendix: conversion calculator | 132 |